A novel active regimen of temozolomide for recurrent glioblastoma

تاریخ : ۱۳۹۳/۰۸/۰۵ / تعداد بازدید : ۲۱۹

Abstract

Twenty-one patients with recurrent or progressive glioblastoma were enrolled in a prospective phase II trial to determine the safety and efficacy of a 1-week on/1-week off regimen of temozolomide administered at 150 mg/m2 on days 1 to 7 and days 15 to 21 of 28-day treatment cycles. Two patients achieved a partial response (10%), and 17 patients (81%) had stable disease. The median progression-free survival was 5 months. The progression-free survival at 6 months was 48%.

Read full article: One week on/one week off: A novel active regimen of temozolomide for recurrent glioblastoma

آخرین مقالات

ثبت مشخصات

نام

پست الکترونیک

کپچا

دیدگاه

A novel active regimen of temozolomide for recurrent glioblastoma

Phase III Dose-Comparison Study of Glatiramer Acetate for Multiple Sclerosis

دانستنی های مفید در خصوص حساسیت دارویی

دلایل و درمان سرگیجه

Efficacy of deferasirox in reducing and preventing cardiac iron overload in β-thalassemia

The Effectiveness of Dimethyl Fumarate Monotherapy in the Treatment of Relapsing-Remitting Multiple Sclerosi

Pharmacology and clinical efficacy of dimethyl fumarate (BG-12) for treatment of relapsing–remitting multiple sclerosis